EMAIL THIS PAGE TO A FRIEND

Tissue engineering. Part A

Combination of BMP2 and MSCs significantly increases bone formation in the rat arterio-venous loop model.


PMID 25135080

Abstract

In this study the induction of bone formation in an axially vascularized bone matrix using mesenchymal stem cells (MSCs) and application of bone morphogenetic protein 2 (BMP2) was analyzed in the arteriovenous loop (AVL) model. An AVL was created in the medial thigh of 42 rats and placed in a porous titanium chamber filled with a particulated porous hydroxyapatite and beta-tricalcium phosphate matrix and fibrin. In group A the fibrin was loaded with 5×10(6) DiI-stained fibrin gel-immobilized primary MSCs from syngenic Lewis rats, in group B the matrix was loaded with 60 μg/mL BMP2 and in group C both, BMP2 and MSCs were applied at implantation time point. After 6 and 12 weeks, specimens were investigated by means of histological, morphometrical, and micro-computed tomography analysis. After implantation of an AVL a dense vascular network was visible in all groups. In group A, newly generated bone islands were detected in the periphery of the main vascular axis. Using BMP2 alone (group B), small islands of newly formed bone were visible evenly distributed in all parts of the constructs. In group C nearly the whole matrix was interspersed with bone formations. In all groups there was an increase of bone formation between the 6 and 12 weeks explantation time points. This study demonstrates for the first time the successful generation of axially vascularized bone substitutes using MSCs and BMP2 in the AVL rat model using a one step procedure. Using the combination of BMP2 and MSCs there was a significant increase of bone formations detectable compared to the BMP2 or MSCs alone groups.

Related Materials

Product #

Image

Description

Molecular Formula

Add to Cart

468495
1,1′-Dioctadecyl-3,3,3′,3′-tetramethylindocarbocyanine perchlorate, 97%
C59H97ClN2O4
42364
1,1′-Dioctadecyl-3,3,3′,3′-tetramethylindocarbocyanine perchlorate, BioReagent, suitable for fluorescence, ≥98.0% (TLC)
C59H97ClN2O4
50553
α-tri-Calcium phosphate, Reagent for transient & stable DNA transfections
Ca3O8P2
16483
β-tri-Calcium phosphate, puriss. p.a., ≥95% β-phase basis (sintered powder)
Ca3O8P2
C3161
Calcium phosphate tribasic, BioReagent, plant cell culture tested, powder
HCa5O13P3
C5267
Calcium phosphate tribasic, 34.0-40.0% Ca basis
HCa5O13P3
M9546
D-Mannitol, BioXtra, ≥98% (GC)
C6H14O6
M9647
D-Mannitol, ACS reagent
C6H14O6
M4125
D-Mannitol, ≥98%
C6H14O6
M1902
D-Mannitol, plant cell culture tested
C6H14O6
M8429
D-Mannitol, meets EP, FCC, USP testing specifications
C6H14O6
63560
D-Mannitol, ACS reagent, for microbiology, ≥99.0%
C6H14O6
17311
D-Mannitol, tested according to Ph.Eur.
C6H14O6
78513
D-Mannitol, ≥99.9999% (metals basis), for boron determination
C6H14O6
702153
Hydroxyapatite, nanoparticles, dispersion, 10 wt. % in H2O, <200 nm particle size (BET)
Ca5HO13P3
H0252
Hydroxyapatite, Type I, buffered aqueous suspension
HCa5O13P3
55497
Hydroxyapatite, ′fast flow′
HCa5O13P3
04238
Hydroxyapatite, puriss., meets analytical specification of Ph. Eur., BP, FCC, E341, ≥90% (calculated on glowed substance)
HCa5O13P3
574791
Hydroxyapatite, synthetic, 99.8% trace metals basis (excludes Mg)
HCa5O13P3
21223
Hydroxyapatite, purum p.a., ≥90% (as Ca3(PO4)2, KT)
HCa5O13P3
289396
Hydroxyapatite, reagent grade, powder, synthetic
HCa5O13P3
677418
Hydroxyapatite, nanopowder, <200 nm particle size (BET), ≥97%, synthetic
HCa5O13P3
693863
Hydroxyapatite, nanopowder, <200 nm particle size (BET), contains 5 wt. % silica as dopant, synthetic
HCa5O13P3
PHR1007
Mannitol, Pharmaceutical Secondary Standard; Certified Reference Material
C6H14O6
1375105
Mannitol, United States Pharmacopeia (USP) Reference Standard
C6H14O6
M0200000
Mannitol, European Pharmacopoeia (EP) Reference Standard
C6H14O6